Liquidia reports FY 2022 revenue $15.9M, net loss $41.0M; YUTREPIA launch path by H1 2024

Liquidia Corp

Revenue $15.9M (+23% YoY); net loss $41.0M ($0.67/share) vs $34.6M loss in 2021.
Legal resolution for YUTREPIA expected late 2023 to H1 2024; PTAB invalidated '793 patent.
Cash $93.3M at Dec 31, 2022; HCRx revenue interest financing up to $100M ($32.5M funded).
New CEO, CMO, Head of Sales; collaboration with Mainbridge for repurposed infusion pump.
Amended Sandoz promotion agreement extends to 2032; pump repair costs split equally.

item 1.01 item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Liquidia Corp reported financial results for full year ended December 31, 2022.

Period: full year ended December 31, 2022
Result: reported results

Exact text from the filing

issued a press release announcing its financial results for the full year ended December 31, 2022, and also provided a corporate update.

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Liquidia Corp amended Fourth Amendment to Promotion Agreement with Sandoz Inc. (effective 2023-03-10).

Action: amendment
Counterparty: Sandoz Inc.
Effective: 2023-03-10

Exact text from the filing

On March 10, 2023, Liquidia PAH, LLC, a Delaware limited liability company (formerly known as RareGen, LLC) (“Liquidia PAH”) and wholly-owned subsidiary of Liquidia Corporation, a Delaware corporation (the “Company”), entered into a Fourth Amendment to Promotion Agreement (the “Fourth Amendment”) with Sandoz Inc. (“Sandoz”).

View on SEC.gov

Browse all earnings releases →

Liquidia Corp filing history →

Source: SEC EDGAR

accession 0001104659-23-032986

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.